Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Piramal Pharma Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,163.58 | 1,748.85 | 1,911.38 | 1,958.57 | 2,552.36 | 1,951.14 | 2,241.75 | 2,204.22 | 2,754.07 | 1,933.71 | 2,043.72 | 2,139.87 | 2,751.77 |
| Expenses + | 1,812.31 | 1,616.53 | 1,645.74 | 1,690.20 | 2,022.43 | 1,746.65 | 1,900.14 | 1,866.48 | 2,193.08 | 1,827.01 | 1,885.03 | 1,944.14 | 2,291.26 |
| Operating Profit | 351.27 | 132.32 | 265.64 | 268.37 | 529.93 | 204.49 | 341.61 | 337.74 | 560.99 | 106.70 | 158.69 | 195.73 | 460.51 |
| OPM % | 16.24% | 7.57% | 13.90% | 13.70% | 20.76% | 10.48% | 15.24% | 15.32% | 20.37% | 5.52% | 7.76% | 9.15% | 16.74% |
| Other Income + | 32.28 | 52.70 | 68.30 | 43.19 | 7.90 | 41.94 | 78.37 | 29.18 | 58.25 | 97.71 | 80.39 | 12.39 | -116.14 |
| Interest | 104.25 | 118.52 | 109.87 | 105.88 | 114.22 | 106.96 | 107.64 | 103.31 | 103.68 | 86.15 | 82.42 | 89.24 | 82.99 |
| Depreciation | 184.41 | 173.61 | 184.51 | 186.32 | 196.13 | 184.55 | 192.22 | 196.81 | 242.76 | 197.28 | 202.84 | 212.74 | 218.38 |
| Profit before tax | 94.89 | -107.11 | 39.56 | 19.36 | 227.48 | -45.08 | 120.12 | 66.80 | 272.80 | -79.02 | -46.18 | -93.86 | 43.00 |
| Tax % | 47.19% | -7.96% | 87.31% | 47.78% | 55.48% | 96.63% | 81.19% | 94.49% | 43.73% | 3.39% | 114.85% | 45.10% | 120.53% |
| Net Profit + | 50.11 | -98.58 | 5.02 | 10.11 | 101.27 | -88.64 | 22.59 | 3.68 | 153.50 | -81.70 | -99.22 | -136.19 | -8.83 |
| EPS in Rs | 0.38 | -0.75 | 0.04 | 0.08 | 0.77 | -0.67 | 0.17 | 0.03 | 1.16 | -0.61 | -0.75 | -1.02 | -0.07 |
Financials of Piramal Pharma Ltd
Annual income statement trend
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales + | 6,315 | 6,559 | 7,082 | 8,171 | 9,151 | 8,869 |
| Expenses + | 4,887 | 5,609 | 6,453 | 6,974 | 7,706 | 7,947 |
| Operating Profit | 1,428 | 950 | 629 | 1,197 | 1,445 | 922 |
| OPM % | 23% | 14% | 9% | 15% | 16% | 10% |
| Other Income + | 230 | 319 | 272 | 172 | 208 | 74 |
| Interest | 163 | 198 | 344 | 448 | 422 | 341 |
| Depreciation | 545 | 586 | 677 | 741 | 816 | 831 |
| Profit before tax | 949 | 485 | -120 | 179 | 415 | -176 |
| Tax % | 12% | 22% | 55% | 90% | 78% | 85% |
| Net Profit + | 835 | 376 | -186 | 18 | 91 | -326 |
| EPS in Rs | -1.41 | 0.13 | 0.69 | -2.45 | ||
| Dividend Payout % | 0% | 18% | 0% | 82% | 20% | 0% |
Financials of Piramal Pharma Ltd
Capital structure and asset base
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 995 | 1,186 | 1,193 | 1,323 | 1,324 | 1,327 |
| Reserves | 4,610 | 5,511 | 5,580 | 6,588 | 6,801 | 6,835 |
| Borrowings + | 3,025 | 4,128 | 5,637 | 4,710 | 4,856 | 5,675 |
| Other Liabilities + | 2,047 | 1,781 | 1,893 | 2,461 | 2,447 | 4,128 |
| Total Liabilities | 10,677 | 12,605 | 14,303 | 15,083 | 15,429 | 17,965 |
| Fixed Assets + | 6,105 | 6,879 | 7,469 | 7,990 | 8,133 | 8,985 |
| CWIP | 627 | 1,172 | 1,419 | 1,116 | 977 | 799 |
| Investments | 123 | 267 | 639 | 385 | 291 | 437 |
| Other Assets + | 3,822 | 4,286 | 4,777 | 5,592 | 6,028 | 7,744 |
| Total Assets | 10,677 | 12,605 | 14,303 | 15,083 | 15,429 | 17,965 |
Financials of Piramal Pharma Ltd
Operating, investing and financing cash movement
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 598 | 766 | 484 | 1,005 | 892 | 1,653 |
| Cash from Investing Activity + | -4,464 | -1,737 | -1,334 | -416 | -488 | -826 |
| Cash from Financing Activity + | 3,977 | 794 | 818 | -422 | -441 | -39 |
| Net Cash Flow | 110 | -177 | -32 | 166 | -37 | 788 |
| Free Cash Flow | -5 | -91 | -461 | 294 | 233 | 776 |
| CFO/OP | 52% | 98% | 107% | 97% | 85% | 202% |
Financials of Piramal Pharma Ltd
Working capital efficiency and return ratios
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 91 | 99 | 93 | 95 | 94 | 89 |
| Inventory Days | 218 | 207 | 227 | 269 | 261 | 345 |
| Days Payable | 163 | 153 | 161 | 190 | 173 | 279 |
| Cash Conversion Cycle | 147 | 153 | 159 | 174 | 182 | 155 |
| Working Capital Days | 44 | 36 | 13 | 21 | 60 | 50 |
| ROCE % | 7% | 2% | 5% | 6% | 3% |